Jeremy M. Schraw, PhD
Assistant Professor, Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine
Departments:
Office location:
6620 Main St
Houston, TX 77030
Get to know Jeremy M. Schraw, PhD
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Post-doctoral Fellowship | Integrative Molecular Epidemiology | 2020 |
| The University of Texas at Austin | PhD | Doctor of Philosophy, Nutritional Sciences | 2016 |
Organizations
| Organization Name | Role |
|---|---|
| American Association for Cancer Research (AACR) | Member |
| Childhood Leukemia International Consortium | Member |
| Children’s Oncology Group (COG) | Member |
| Society for Birth Defects Research and Prevention | Member |
Honors and awards
- 2024
-
F. Clarke Fraser New Investigator Award, Society for Birth Defects Research and Prevention
- 2020
-
Wilson Presentation Award, Society for Birth Defects Research and Prevention
- 2021
-
Junior Faculty Publication Award, Texas Children's Hospital
-
Young Investigator Talent Award, International Society of Paediatric Oncology (SIOP)
-
Junior Investigator Award, Brain Tumor Epidemiology Consortium
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Highlights
Study examines prevalence of birth defects following DPR implementation
BCM.edu
Research Area:
Epidemiology (Cancer and Hematology)
Dr. Jeremy Schraw is a molecular epidemiologist whose research interests include structural birth defects and childhood cancer. He uses large-scale, population-based registry data and genomics to identify risk factors for these phenotypes and to understand the basis for their co-occurrence. He has a background in nutritional epidemiology, and is also interested in how diet and body composition affect cancer risk and outcomes.
In this line of investigation, he applies both targeted and non-targeted metabolomics techniques to develop prognostic biomarkers and identify potential therapeutic targets in children with leukemia.
He is active in several scientific organizations, including the Children’s Oncology Group, Society for Birth Defects Research and Prevention, and the Childhood Leukemia International Consortium.